Andrea Mambrini
Academy for Urban School Leadership
CancerInternal medicineSurgeryOncologySingle-nucleotide polymorphismChemotherapyPancreatic diseasePerformance statusCisplatinPancreatic cancerGemcitabineIrinotecanEpirubicinRegimenCombination chemotherapyColorectal cancerGeneticsMedicineBiologyGastroenterology
96Publications
20H-index
1,616Citations
Publications 93
Newest
#1Isabella FrigerioH-Index: 17
#2Salvatore PaiellaH-Index: 23
Last. G. FiorentiniH-Index: 14
view all 0 authors...
Abstract null null Background null Local ablation of pancreatic cancer has been suggested as an option to manage locally advanced pancreatic cancer (LAPC) although no robust evidence has been published to date to support its application. The aim of this study is to compare overall survival (OS) and progression-free survival (PFS) in patients receiving both radiofrequency ablation (RFA) and conventional chemoradiotherapy (CHRT) with patients receiving CHRT only. null null null Methods null This i...
Source
#1Davide MelisiH-Index: 31
Last. Giovanni ButturiniH-Index: 51
view all 21 authors...
Abstract Background Pancreaticoduodenal cancer (PDC) is a group of malignant tumors arising in the ampullary region, which lack approved targeted therapies for their treatment. Methods This retrospective, observational study is based on Secondary Data Use (SDU) previously collected during a multicenter collaboration, which were subsequently entered into a predefined database and analyzed. FoundationOne CDx or Liquid, a next-generation DNA sequencing (NGS) service, was used to identify genomic al...
Source
#1Gerardo RosatiH-Index: 21
#2Sara LonardiH-Index: 52
Last. Valter Torri (Mario Negri Institute for Pharmacological Research)H-Index: 84
view all 142 authors...
BACKGROUND Previous studies on oxaliplatin and fluoropyrimidines as adjuvant therapy in older patients with stage III colon cancer (CC) produced conflicting results. PATIENTS AND METHODS We assessed the impact of age on time to tumour recurrence (TTR), disease-free survival (DFS), cancer-specific survival (CSS), and overall survival (OS) in 2360 patients with stage III CC (1667 aged <70 years and 693 ≥ 70 years) randomised to receive 3 or 6 months of FOLFOX or CAPOX within the frame of the phase...
Source
#1Gerardo RosatiH-Index: 21
#2F. GalliH-Index: 8
Last. R. LabiancaH-Index: 22
view all 19 authors...
2 CitationsSource
Last. Carlo AscheleH-Index: 21
view all 20 authors...
Background: Cancer patients are more susceptible to infections and potentially at higher risk to develop COVID-19 Tumor type and antitumor treatment may also affect both the susceptibility to and the severity of SARS COV-2 Methods: To analyze the distribution of patients who developed COVID-19 during active antineoplastic therapy and the related clinical course by tumor type, stage and class of oncologic treatment (chemo, immune, biologic, other) a multicenter, retro-prospective, observational s...
Source
#2Manuel Gentiluomo (UniPi: University of Pisa)H-Index: 6
Last. Daniele Campa (UniPi: University of Pisa)H-Index: 34
view all 66 authors...
Background Most cases of pancreatic ductal adenocarcinoma (PDAC) are asymptomatic in early stages, and the disease is typically diagnosed in advanced phases, resulting in very high mortality. Tools to identify individuals at high risk of developing PDAC would be useful to improve chances of early detection. Objective We generated a polygenic risk score (PRS) for PDAC risk prediction, combining the effect of known risk SNPs, and carried out an exploratory analysis of a multifactorial score. Metho...
5 CitationsSource
#1Fausto PetrelliH-Index: 45
#2Roberto LabiancaH-Index: 76
Last. Alberto SobreroH-Index: 62
view all 23 authors...
Importance The addition of oxaliplatin to the standard 6-month fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer has been reported to reduce the risk of relapse although it does not increase survival. The Three or Six Colon Adjuvant (TOSCA) trial compared 3 months with 6 months of adjuvant fluoropyrimidine and oxaliplatin-based chemotherapy in patients with stage III colon cancer. The utility remains unknown. Objective To assess the noninferiority and toxic effects of 3 vs 6...
11 CitationsSource
#1Chiara Cremolini (UniPi: University of Pisa)H-Index: 44
#2Carlotta Antoniotti (UniPi: University of Pisa)H-Index: 20
Last. Alfredo Falcone (UniPi: University of Pisa)H-Index: 79
view all 40 authors...
Background: The triplet FOLFOXIRI (fluorouracil, L-leucovorin, oxaliplatin, and irinotecan) plus bevacizumab showed improved outcomes of patients with metastatic colorectal cancer, when compared to FOLFIRI (fluorouracil, Lleucovorin, and irinotecan) plus bevacizumab. However, the actual benefit of the upfront exposure to the three cytotoxics when compared with a preplanned sequential strategy of doublets was not clear, as well as the feasibility and efficacy of therapies after progression. To th...
1 CitationsSource
#2Donatella SartiH-Index: 9
Last. Stefano Guadagni (University of L'Aquila)H-Index: 22
view all 9 authors...
Background: Pancreatic adenocarcinoma has a poor prognosis, resulting in a <10% survival rate at 5 years. Modulated electro-hyperthermia (mEHT) has been increasingly used for pancreatic cancer pall...
6 CitationsSource
#1Ofure Obazee (DKFZ: German Cancer Research Center)H-Index: 9
#2Livia ArchibugiH-Index: 13
Last. Federico Canzian (DKFZ: German Cancer Research Center)H-Index: 82
view all 61 authors...
: Rare truncating BRCA2 K3326X (rs11571833) and pathogenic CHEK2 I157T (rs17879961) variants have previously been implicated in familial pancreatic ductal adenocarcinoma (PDAC), but not in sporadic cases. The effect of both mutations in important DNA repair genes on sporadic PDAC risk may shed light on the genetic architecture of this disease. Both mutations were genotyped in germline DNA from 2,935 sporadic PDAC cases and 5,626 control subjects within the PANcreatic Disease ReseArch (PANDoRA) c...
11 CitationsSource